Clinician Perspective on Once-Daily Zanubrutinib Dosing for B-Cell Malignancies at a Single Center
{{output}}
Zanubrutinib, a next-generation, irreversible, highly potent, and selective Bruton tyrosine kinase inhibitor, is approved by the U.S. Food and Drug Administration to treat patients with B-cell malignancies in 2 dose regimens: 160 mg twice daily (BID) and 320 m... ...
